Floatz logo

Modified Vaccinia Virus Ankara-5T4 Antigen

Prostate Neoplasm

The Methodist Hospital Research InstitutevaccinePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
73/ 100

Competitive context

70 Active assets in the Prostate Neoplasm cohort.

Asset / SponsorPhaseRating
Docetaxel
Merck Sharp & Dohme LLC
Phase 4BBB
Degarelix
Novartis Pharmaceuticals
Phase 4BBB
Prednisone
Merck Sharp & Dohme LLC
Phase 3BBB
Abiraterone
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Leuporelin
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Modified Vaccinia Virus Ankara-5T4 Antigen is also rated in:

renal cell carcinomaDormant
B
Indicative · Phase 2
62 / 100
View asset →
clear cell renal carcinomaDormant
B
Indicative · Phase 3
60 / 100
View asset →
peritoneum cancerDormant
B
Indicative · Phase 2
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →